Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Key TakeawaysYou can take Zofran up to 3 times a day for 1-2 days after completing your cancer treatment until it is no longer needed. If you are experiencing nausea and vomiting after surgery or cancer treatment such as chemotherapy and radiation treatment, your doctor may prescribe a medication called ondansetron (brand name: Zofran). You can take Zofran up to 3 times a day for 1-2 days after completing your cancer treatment until it is no longer needed. Make sure to adhere to the Zofran schedule prescribed by your doctor and take this medication regularly to get maximum benefits. Please continue reading to learn more about Zofran, including its uses, dosage, and frequency of use. We will also talk about how it works for the prevention of nausea and vomiting, whether it is safe to use during pregnancy, potential drug interactions, and tips on safe Zofran use. What is ondansetron (Zofran)?Ondansetron (Zofran, Zofran ODT) is a prescription medication used to prevent nausea and vomiting for cancer patients after chemotherapy and radiation treatment. It is also used to treat nausea after surgery. There may be additional uses of ondansetron (Zofran)—your doctor or pharmacist can give you further information.Zofran is available in various dosage forms, including oral tablets (4 mg, 8 mg, and 24 mg), orally disintegrating tablets and oral films (4 mg and 8 mg), an oral solution (4 mg/5 mL), and injection vials (2 mg/mL).Dosage forms such as the orally disintegrating tablet, the oral liquid, and the oral film may cause less of a nauseating feeling than that caused by swallowing a tablet. How does Zofran work?Zofran is an antiemetic that belongs to a group of drugs called 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance in the body that can trigger nausea and initiate a vomiting reflex.What is the usual dose of Zofran?The usual dose of ondansetron (Zofran) in adults and children is as follows:AdultsSevere nausea and vomiting due to chemotherapy: a single 24-mg dose to be taken 30 minutes before the start of a single day of highly emetogenic (vomiting-inducing) chemotherapy. Moderate nausea and vomiting due to chemotherapy: An 8-mg tablet is administered 30 minutes before the start of chemotherapy, followed by another 8-mg dose 8 hours later. After the completion of chemotherapy, 8 mg of Zofran should be taken every 12 hours for 1 to 2 days.Radiation therapy: An 8-mg ondansetron is taken 1-2 hours before radiation therapy. After the first dose, the regimen of 8 mg every 8 hours is recommended depending on the type and the location of radiation.Post-operative (after-surgery) nausea and vomiting: 16 mg of ondansetron is to be administered 1 hour before anesthesia. Children:Age 4 to 11: Ondansetron 8 mg oral tablet The recommended oral dosage is one 8-mg ondansetron hydrochloride tablet or one 8-mg ondansetron orally disintegrating tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of ondansetron hydrochloride oral solution given 3 times a day. Ondansetron 8 mg oral tablet Tablets, Oral Solution and Injection (ondansetron hydrochloride dihydrate) 4 mg and 8 mg ondansetron hydrochloride dihydrate tablets 4 mg/5 mL ondansetron oral solution, USP 2 mg/mL ondansetron hydrochloride dihydrate for injection PrZOFRAN ODT (Oral Disintegrating Tablets) (ondansetron) 4 mg and 8 mg ondansetron orally disintegrating tablets Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Each 4-mg Ondansetron Orally Disintegrating Tablet, USP for oral administration contains 4 mg ondansetron base. Each 8-mg Ondansetron Orally Disintegrating Tablet, USP for oral administration contains 8 mg ondansetron base. Ondansetron 8 mg oral tablet 10,11,12.Cytotoxic chemotherapy and radiotherapy are associated with the release of serotonin (5-HT) from enterochromaffin cells of the small intestine, presumably initiating a vomiting reflex through stimulation of 5-HT3 receptors located on vagal afferents 10,11,12. Ondansetron may block the initiation of this reflex. Activation of vagal afferents may also cause a central release of serotonin from the chemoreceptor trigger zone of the area postrema, located on the floor of the fourth ventricle 10,11,12. Thus, the antiemetic effect of ondansetron is probably due to the selective antagonism of 5-HT3 receptors on neurons located in either the peripheral or central nervous systems, or both 10,11,12.Although the mechanisms of action of ondansetron in treating postoperative nausea and vomiting and cytotoxic induced nausea and vomiting may share similar pathways, the role of ondansetron in opiate-induced emesis has not yet been formally established 11,12.TargetActionsOrganismA5-hydroxytryptamine receptor 3AantagonistHumansU5-hydroxytryptamine receptor 4agonistHumansUMu-type opioid receptorother/unknownHumansU5-hydroxytryptamine receptor 1Aother/unknownHumansU5-hydroxytryptamine receptor 1Bother/unknownHumansAbsorptionOndansetron is absorbed from the gastrointestinal tract and undergoes some limited first-pass metabolism 10. Mean bioavailability in healthy subjects, following administration of a single 8-mg tablet, was recorded as being approximately 56% to 60% 10,11,12. Bioavailability is also slightly enhanced by the presence of food 10.Ondansetron systemic exposure does not increase proportionately to dose 10. The AUC from a 16-mg tablet was 24% greater than predicted from an 8-mg tablet dose 10. This may reflect some reduction of first-pass metabolism at higher oral doses 10.Volume of distributionThe volume of distribution of ondansetron has been recorded as being approximately 160L 5.Protein bindingThe plasma protein binding associated with ondansetron was documented as approximately 73% 11,12.MetabolismIn vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P450 enzymes, including CYP1A2, CYP2D6 and CYP3A4 10,11,12. In terms of overall ondansetron turnover, CYP3A4 played the predominant role 10,11,12. Because of the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g. CYP2D6 enzyme deficiency) will be compensated by others and may result in little change in overall rates of ondansetron clearance 10,11,12.Following oral or IV administration, ondansetron is extensively metabolised and excreted in the urine Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Tablets, Oral Solution and Injection (ondansetron hydrochloride dihydrate) 4 mg and 8 mg ondansetron hydrochloride dihydrate tablets 4 mg/5 mL ondansetron oral solution, USP 2 mg/mL ondansetron hydrochloride dihydrate for injection PrZOFRAN ODT (Oral Disintegrating Tablets) (ondansetron) 4 mg and 8 mg ondansetron orally disintegrating tablets Ondansetron 8 mg oral tablet Tablets, Oral Solution and Injection (ondansetron hydrochloride dihydrate) 4 mg and 8 mg ondansetron hydrochloride dihydrate tablets 4 mg/5 mL ondansetron oral solution, USP 2 mg/mL ondansetron hydrochloride dihydrate for injection PrZOFRAN ODT (Oral Disintegrating Tablets) (ondansetron) 4 mg and 8 mg ondansetron orally disintegrating tablets Ondansetron 8 mg oral tablet Tablets, Oral Solution and Injection (ondansetron hydrochloride dihydrate) 4 mg and 8 mg ondansetron hydrochloride dihydrate tablets 4 mg/5 mL ondansetron oral solution, USP 2 mg/mL ondansetron hydrochloride dihydrate for injection PrZOFRAN ODT (Oral Disintegrating Tablets) (ondansetron) 4 mg and 8 mg ondansetron orally disintegrating tablets Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet MINT-ONDANSETRON ODT. (Oral Disintegrating Tablets). (ondansetron). 4 mg and 8 mg ondansetron orally disintegrating tablets, Mfr. Std Ondansetron 8 mg oral tablet And faeces 10,11,12. In humans, less than 10% of the dose is excreted unchanged in the urine 10,11,12. The major urinary metabolites are glucuronide conjugates (45%), sulphate conjugates (20%) and hydroxylation products (10%) 10,11,12. The primary metabolic pathway is subsequently hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation 10,11,12. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron 10,11,12.Hover over products below to view reaction partnersRoute of eliminationFollowing oral or IV administration, ondansetron is extensively metabolised and excreted in the urine and faeces 11,12.Half-lifeThe half-life of ondansetron after either an 8 mg oral dose or intravenous dose was approximately 3-4 hours and could be extended to 6-8 hours in the elderly 11,12. ClearanceThe clearance values determined for ondansetron in various patient age groups were recorded as approximately 0.38 L/h/kg in normal adult volunteers aged 19-40 yrs, 0.32 L/h/kg in normal adult volunteers aged 61-74 yrs, 0.26 L/h/kg in normal adult volunteers aged >=75 yrs Label.Adverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.ToxicityAt present, there is little information concerning overdosage with ondansetron 10,11,12. Nevertheless, there have been certain cases of somewhat idiosyncratic adverse effects associated with particular dosages of ondansetron used 10,11,12.“Sudden blindness” (amaurosis) of 2 to 3 minutes duration plus severe constipation occurred in one patient that was administered 72 mg of ondansetron intravenously as a single dose 10,11,12. Hypotension (and faintness) occurred in another patient that took 48 mg of oral ondansetron 10,11,12. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree heart block was observed 10,11,12. Neuromuscular abnormalities, autonomic instability, somnolence, and a brief generalized tonic-clonic seizure (which resolved after a dose of benzodiazepine) were observed in a 12-month-old infant who ingested seven or eight 8-mg ondansetron tablets (approximately forty times the recommended 0.1-0.15 mg/kg dose Ondansetron 8 mg oral tablet Four- and 8 mg doses of either of ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet ondansetron 8 mg orally disintegrating tablet, 4; ondansetron 8 mg orally disintegrating tablet, 10; ondansetron 4 mg tablet, 4; ondansetron 4 mg tablet, 10; Ondansetron 8 mg oral tablet RxNORM ; Synonyms. ondansetron 8 MG (as ondansetron HCl dihydrate 10 MG) Oral Tablet. ondansetron HCl 8 MG Oral Tablet ; ID. Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet More More about Promethazine More about Ondansetron More about Metoclopramide Ratings & Reviews Promethazine has an average rating of 7.3 out of 10 from a total of 388 ratings on Drugs.com. 66% of reviewers reported a positive effect, while 21% reported a negative effect. Ondansetron has an average rating of 7.8 out of 10 from a total of 492 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 18% reported a negative effect. Metoclopramide has an average rating of 3.9 out of 10 from a total of 516 ratings on Drugs.com. 29% of reviewers reported a positive effect, while 63% reported a negative effect. View all 388 reviews View all 492 reviews View all 516 reviews Drug Class Antihistamines Phenothiazine antiemetics 5HT3 receptor antagonists GI stimulants Miscellaneous antiemetics Side Effects Promethazine side effects Ondansetron side effects Metoclopramide side effects Generic Availability Lower cost generic Lower cost generic Lower cost generic Pricing and Coupons * Prices are without insurance Quantity 1 tablet Strength 25 mg Per Unit* $9.39 Cost* $9.39 View all Promethazine prices Quantity 20 mL Strength 2 mg/mL Per Unit* $0.66 Cost* $13.14 View all Ondansetron prices Quantity 100 each Strength 10 mg Per Unit* $0.27 Cost* $27.49 View all Metoclopramide prices Get free Discount Card Get free Discount Card Get free Discount Card Dosage Forms Available Injectable solution Oral syrup Oral tablet Rectal suppository Injectable solution Oral solution Oral tablet Oral tablet, disintegrating Injectable solution Oral syrup Oral tablet Oral tablet, disintegrating Brand Names Adgan, Anergan 50, Antinaus 50, Phenadoz, Promethegan N/A Gimoti, Maxolon, Reglan Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. 16 hours 4 hours 8 hours CSA Schedule ** View glossary of terms Is not subject ondansetron oral. -. 8 mg tablet ; ondansetron oral. -. 4 mg tablet. Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet orally disintegrating tablets. 4mg; 8mg; 16mg; 24mg. Chemotherapy-Induced 8 mg tablet. ondansetron oral. -. 4 mg tablet. ondansetron oral. -. 8 mg tablet. Ondansetron 8 mg oral tablet ondansetron oral. -. 8 mg tablet ; ondansetron oral. -. 4 mg tablet. Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Tablets, Oral Solution and Injection (ondansetron hydrochloride dihydrate) 4 mg and 8 mg ondansetron hydrochloride dihydrate tablets 4 mg/5 mL ondansetron oral solution, USP 2 mg/mL ondansetron hydrochloride dihydrate for injection PrZOFRAN ODT (Oral Disintegrating Tablets) (ondansetron) 4 mg and 8 mg ondansetron orally disintegrating tablets Ondansetron 8 mg oral tablet More More about Promethazine More about Ondansetron More about Metoclopramide Ratings & Reviews Promethazine has an average rating of 7.3 out of 10 from a total of 388 ratings on Drugs.com. 66% of reviewers reported a positive effect, while 21% reported a negative effect. Ondansetron has an average rating of 7.8 out of 10 from a total of 492 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 18% reported a negative effect. Metoclopramide has an average rating of 3.9 out of 10 from a total of 516 ratings on Drugs.com. 29% of reviewers reported a positive effect, while 63% reported a negative effect. View all 388 reviews View all 492 reviews View all 516 reviews Drug Class Antihistamines Phenothiazine antiemetics 5HT3 receptor antagonists GI stimulants Miscellaneous antiemetics Side Effects Promethazine side effects Ondansetron side effects Metoclopramide side effects Generic Availability Lower cost generic Lower cost generic Lower cost generic Pricing and Coupons * Prices are without insurance Quantity 1 tablet Strength 25 mg Per Unit* $9.39 Cost* $9.39 View all Promethazine prices Quantity 20 mL Strength 2 mg/mL Per Unit* $0.66 Cost* $13.14 View all Ondansetron prices Quantity 100 each Strength 10 mg Per Unit* $0.27 Cost* $27.49 View all Metoclopramide prices Get free Discount Card Get free Discount Card Get free Discount Card Dosage Forms Available Injectable solution Oral syrup Oral tablet Rectal suppository Injectable solution Oral solution Oral tablet Oral tablet, disintegrating Injectable solution Oral syrup Oral tablet Oral tablet, disintegrating Brand Names Adgan, Anergan 50, Antinaus 50, Phenadoz, Promethegan N/A Gimoti, Maxolon, Reglan Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. 16 hours 4 hours 8 hours CSA Schedule ** View glossary of terms Is not subject Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet MINT-ONDANSETRON ODT. (Oral Disintegrating Tablets). (ondansetron). 4 mg and 8 mg ondansetron orally disintegrating tablets, Mfr. Std Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Base. Melt the base over a water bath (Tenjarla SN, Ward ES, and Fox JL, "Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux Through Rabbit Rectal Membrane," Int J Pharm Compound, 1998, 2(1):83-8.Trissel LA, Trissel's Stability of Compounded Formulations, Washington, DC: American Pharmaceutical Association, 1996.AdministrationOral: Oral dosage forms should be administered 30 minutes prior to chemotherapy; 1 to 2 hours before radiation; 30 to 60 minutes prior to surgery or induction of anesthesiaOrally disintegrating tablets: Do not remove from blister until needed. Peel backing off the blister, do not attempt to push tablet through the foil. Using dry hands, place tablet on tongue and allow to dissolve. Swallow with saliva (no need to administer with liquids).Oral soluble film: Do not remove from pouch until immediately before use. Using dry hands, place film on top of tongue and allow to dissolve (4 to 20 seconds). Swallow with or without liquid. If using more than one film, each film should be allowed to dissolve completely before administering the next film.IM: Should be administered undiluted.IV:IVPB: Infuse diluted solution over 15 minutesChemotherapy-induced nausea and vomiting: Give first dose 30 minutes prior to beginning chemotherapy.IV push: Prevention of postoperative nausea and vomiting: Single doses may be administered IV injection as undiluted solution over at least 30 seconds but preferably over 2 to 5 minutes Dietary ConsiderationsSome products may contain phenylalanine. StorageOral soluble film: Store between 20°C and 25°C (68°F and 77°F). Store pouches in cartons; keep film in individual pouch until ready to use.Oral solution: Store between 15°C and 30°C (59°F and 86°F). Protect from light.Tablet: Store between 2°C and 30°C (36°F and 86°F).Vial: Store between 2°C and 30°C (36°F and 86°F). Protect from light. Chemically and physically stable when mixed in D5W or NS for 48 hours at room temperature; however, diluents generally do not contain a preservative and sterile precautions should be observed. After dilution, do not use beyond 24 hours.Premixed bag in D5W: Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F); may refrigerate; avoid freezing and excessive heat; protect from light. Ondansetron Images ondansetron 4 mg ondansetron 8 mg ondansetron 4 mg ondansetron 8 mg ondansetron 4 mg ondansetron 8 mg Drug InteractionsAmiodarone: May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Consider therapy modificationApomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. Avoid combinationBosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapyCYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapyCYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling. Consider therapy modificationDabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Four- and 8 mg doses of either of ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Tablets, Oral Solution and Injection (ondansetron hydrochloride dihydrate) 4 mg and 8 mg ondansetron hydrochloride dihydrate tablets 4 mg/5 mL ondansetron oral solution, USP 2 mg/mL ondansetron hydrochloride dihydrate for injection PrZOFRAN ODT (Oral Disintegrating Tablets) (ondansetron) 4 mg and 8 mg ondansetron orally disintegrating tablets Ondansetron 8 mg oral tablet Ondansetron Hydrochloride Tablets and Ondansetron Orally Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg. Ondansetron 8 mg oral tablet ondansetron 4 mg orally disintegrating tablet, 4; ondansetron 4 mg orally disintegrating tablet, 10; ondansetron 4 mg tablet, 10; ondansetron 8 mg tablet, 4; Ondansetron 8 mg oral tablet ondansetron 8 mg orally disintegrating tablet, 4; ondansetron 8 mg orally disintegrating tablet, 10; ondansetron 4 mg tablet, 4; ondansetron 4 mg tablet, 10; Ondansetron 8 mg oral tablet Base. Melt the base over a water bath (Tenjarla SN, Ward ES, and Fox JL, "Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux Through Rabbit Rectal Membrane," Int J Pharm Compound, 1998, 2(1):83-8.Trissel LA, Trissel's Stability of Compounded Formulations, Washington, DC: American Pharmaceutical Association, 1996.AdministrationOral: Oral dosage forms should be administered 30 minutes prior to chemotherapy; 1 to 2 hours before radiation; 30 to 60 minutes prior to surgery or induction of anesthesiaOrally disintegrating tablets: Do not remove from blister until needed. Peel backing off the blister, do not attempt to push tablet through the foil. Using dry hands, place tablet on tongue and allow to dissolve. Swallow with saliva (no need to administer with liquids).Oral soluble film: Do not remove from pouch until immediately before use. Using dry hands, place film on top of tongue and allow to dissolve (4 to 20 seconds). Swallow with or without liquid. If using more than one film, each film should be allowed to dissolve completely before administering the next film.IM: Should be administered undiluted.IV:IVPB: Infuse diluted solution over 15 minutesChemotherapy-induced nausea and vomiting: Give first dose 30 minutes prior to beginning chemotherapy.IV push: Prevention of postoperative nausea and vomiting: Single doses may be administered IV injection as undiluted solution over at least 30 seconds but preferably over 2 to 5 minutes Dietary ConsiderationsSome products may contain phenylalanine. StorageOral soluble film: Store between 20°C and 25°C (68°F and 77°F). Store pouches in cartons; keep film in individual pouch until ready to use.Oral solution: Store between 15°C and 30°C (59°F and 86°F). Protect from light.Tablet: Store between 2°C and 30°C (36°F and 86°F).Vial: Store between 2°C and 30°C (36°F and 86°F). Protect from light. Chemically and physically stable when mixed in D5W or NS for 48 hours at room temperature; however, diluents generally do not contain a preservative and sterile precautions should be observed. After dilution, do not use beyond 24 hours.Premixed bag in D5W: Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F); may refrigerate; avoid freezing and excessive heat; protect from light. Ondansetron Images ondansetron 4 mg ondansetron 8 mg ondansetron 4 mg ondansetron 8 mg ondansetron 4 mg ondansetron 8 mg Drug InteractionsAmiodarone: May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Consider therapy modificationApomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. Avoid combinationBosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapyCYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapyCYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling. Consider therapy modificationDabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Ondansetron tablet 8 mg also contains polysorbate 80 and iron oxide yellow. Each 4 mg ondansetron orally disintegrating tablet for oral administration contains 4 mg ondansetron, USP. Each 8 mg ondansetron orally disintegrating tablet for oral administration contains 8 mg ondansetron, USP. Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Patient is symptomatic. Repeat doses given in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective.Infants and Children: IV:≤40 kg: 0.1 mg/kg/dose as a single dose; maximum dose: 4 mg/dose>40 kg: 4 mg/dose as a single doseAdolescents: IM, IV: 4 mg/dose as a single doseRadiation-induced nausea and vomiting, prevention: Limited data available: Oral:Weight-directed dosing: Infants ≥5 months, Children, and Adolescents: 0.2 mg/kg/dose (maximum dose: 8 mg/dose) administered every 8 hours throughout total body irradiation (TBI) prior to HSCT (n=68; mean age: 6.7 years; range: 5 months to 20 years); doses were generally rounded to 4 mg/dose in children 4 to 11 years and 8 mg/dose in children ≥12 years and adolescents (Applegate 1998)Alternate weight-based dosing: Children and Adolescents: 0.15 mg/kg/dose administered 3 to 4 times daily throughout TBI (n=33; mean age: 9 years; range: 13 months to 16 years) (Farah 1998)Fixed dose: Note: Derived from rounding weight-based (0.2 mg/kg/dose) doses (Applegate 1998)Children 4 to 11 years: 4 mg every 8 hours throughout total body irradiation (TBI) prior to HSCTChildren ≥12 years and Adolescents: 8 mg every 8 hours throughout total body irradiation (TBI) prior to HSCTAlternate fixed-dosing: Children ≥9 years and Adolescents: 8 mg every 12 hours on days of TBI prior to bone marrow transplantation (age range: 9 to 67 years; median age range: 39 to 49 years). Note: Administered in combination with dexamethasone (Bredeson 2002).ReconstitutionVial:Prevention of chemotherapy-induced nausea and vomiting: Dilution is required prior to IV infusion. Dilute in 50 mL D5W or NS. In pediatric patients between 6 months and 1 year of age and/or ≤10 kg, may dilute in 10 to 50 mL D5W or NS, depending on fluid needs of the patient. Use diluted solutions within 24 hours of preparation.Prevention of postoperative nausea and vomiting: No dilution is required.Extemporaneously PreparedNote: Commercial oral solution is available (0.8 mg/mL)If commercial oral solution is unavailable, a 0.8 mg/mL syrup may be made with ondansetron tablets, Ora-Plus® (Paddock), and any of the the following syrups: Cherry syrup USP, Syrpalta® (HUMCO), Ora-Sweet® (Paddock), or Ora-Sweet® Sugar-Free (Paddock). Crush ten 8 mg tablets in a mortar and reduce to a fine powder (flaking of the tablet coating occurs). Add 50 mL Ora-Plus® in 5 mL increments, mixing thoroughly; mix while adding the chosen syrup in incremental proportions to almost 100 mL; transfer to a calibrated bottle, rinse mortar with syrup, and add sufficient quantity of syrup to make 100 mL. Label "shake well" and "refrigerate". Stable for 42 days refrigerated (Trissel 1996).Rectal suppositories: Calibrate a suppository mold for the base being used. Determine the displacement factor (DF) for ondansetron for the base being used (Fattibase® = 1.1; Polybase® = 0.6). Weigh the ondansetron tablet(s). Divide the tablet weight by the DF; this result is the weight of base displaced by the drug. Subtract the weight of base displaced from the calculated weight of base required for each suppository. Grind the ondansetron tablets in a mortar and reduce to a fine powder. Weigh out the appropriate weight of suppository Four- and 8 mg doses of either of ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet ondansetron oral. -. 8 mg tablet ; ondansetron oral. -. 4 mg tablet. Ondansetron 8 mg oral tablet MINT-ONDANSETRON ODT. (Oral Disintegrating Tablets). (ondansetron). 4 mg and 8 mg ondansetron orally disintegrating tablets, Mfr. Std Ondansetron 8 mg oral tablet 4 mg and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron tablets and may be used interchangeably. One 24 mg ondansetron tablet is bioequivalent to and interchangeable with three 8 mg ondansetron tablets. Ondansetron 8 mg oral tablet
ondansetron 8 MG Disintegrating Oral Tablet
Ondansetron, 8 MG Orally Disintegrating Tablet